Ultragenyx Pharmaceutical Inc (FRA:UP0)
€ 46 -0.2 (-0.43%) Market Cap: 4.37 Bil Enterprise Value: 3.82 Bil PE Ratio: 0 PB Ratio: 13.49 GF Score: 79/100

Ultragenyx Pharmaceutical Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript

Apr 03, 2023 / 02:45PM GMT
Release Date Price: €37 (+4.52%)
Debjit D. Chattopadhyay
Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology

Right. Good morning, and thank you for joining us -- I think Fifth Annual Guggenheim Genomic Medicines on Rare Disease Conference. I'm Debjit and my privilege to host Emil Kakkis, the CEO of Ultragenyx.

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - Founder, President, CEO & Director

Thank you.

Debjit D. Chattopadhyay
Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology

Thank you, Emil, for being here. It's going to be a pretty interesting second half for you guys.

Questions & Answers

Debjit D. Chattopadhyay
Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology

So maybe we can start with the upcoming catalysts and where the pipeline currently stands?

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - Founder, President, CEO & Director

Sure. We will

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot